MA50096A - Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux - Google Patents
Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non virauxInfo
- Publication number
- MA50096A MA50096A MA050096A MA50096A MA50096A MA 50096 A MA50096 A MA 50096A MA 050096 A MA050096 A MA 050096A MA 50096 A MA50096 A MA 50096A MA 50096 A MA50096 A MA 50096A
- Authority
- MA
- Morocco
- Prior art keywords
- free dna
- lipid nanoparticle
- dna vectors
- nanoparticle formulations
- viral capside
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Botany (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556334P | 2017-09-08 | 2017-09-08 | |
| US201762556333P | 2017-09-08 | 2017-09-08 | |
| US201762556381P | 2017-09-09 | 2017-09-09 | |
| US201862675324P | 2018-05-23 | 2018-05-23 | |
| US201862675317P | 2018-05-23 | 2018-05-23 | |
| US201862675322P | 2018-05-23 | 2018-05-23 | |
| US201862675327P | 2018-05-23 | 2018-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50096A true MA50096A (fr) | 2020-07-15 |
Family
ID=65635269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050096A MA50096A (fr) | 2017-09-08 | 2018-09-07 | Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210059953A1 (fr) |
| EP (1) | EP3679148A4 (fr) |
| JP (3) | JP2020537493A (fr) |
| KR (1) | KR102696307B1 (fr) |
| CN (1) | CN111295448A (fr) |
| AU (1) | AU2018330208B2 (fr) |
| BR (1) | BR112020004219A2 (fr) |
| CA (1) | CA3075180A1 (fr) |
| CO (1) | CO2020002262A2 (fr) |
| IL (1) | IL272799B2 (fr) |
| MA (1) | MA50096A (fr) |
| MX (1) | MX2020002501A (fr) |
| MY (1) | MY209906A (fr) |
| PH (1) | PH12020500466A1 (fr) |
| SG (1) | SG11202000765PA (fr) |
| WO (1) | WO2019051289A1 (fr) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY203184A (en) | 2017-08-09 | 2024-06-13 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| CA3091250A1 (fr) * | 2018-02-14 | 2019-08-22 | Generation Bio Co. | Vecteurs d'adn non viraux et utilisations associees pour la production d'anticorps et de proteines de fusion |
| EP3796893A1 (fr) * | 2018-05-23 | 2021-03-31 | Modernatx, Inc. | Administration d'adn |
| MX2021001599A (es) | 2018-08-09 | 2021-07-02 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y sus usos para la terapia genica no viral. |
| CA3147875A1 (fr) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Compositions a recombinase et leurs methodes d'utilisation |
| CA3147728A1 (fr) * | 2019-08-12 | 2021-02-18 | Generation Bio Co. | Methodes et compositions pour reduire des reponses immunitaires associees a une therapie genique ou d'acide nucleique |
| CA3150452A1 (fr) | 2019-09-06 | 2021-03-11 | Generation Bio Co. | Compositions de nanoparticules lipidiques comprenant de l'adn a extremites fermees et des lipides clivables et leurs procedes d'utilisation |
| JP2023502576A (ja) * | 2019-11-22 | 2023-01-25 | ジェネレーション バイオ カンパニー | イオン化可能な脂質およびそれらのナノ粒子組成物 |
| CN110974954B (zh) * | 2019-12-24 | 2021-03-16 | 珠海丽凡达生物技术有限公司 | 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| CA3179444A1 (fr) | 2020-05-20 | 2021-11-25 | Avak Kahvejian | Compositions immunogenes et leurs utilisations |
| AU2021275223A1 (en) | 2020-05-20 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc. | Coronavirus antigen compositions and their uses |
| KR20230029685A (ko) | 2020-05-29 | 2023-03-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | Trem 조성물 및 이에 관련된 방법 |
| WO2021243301A2 (fr) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc. | Compositions à base de trem et procédés associés |
| CN116437964A (zh) * | 2020-07-17 | 2023-07-14 | 世代生物公司 | 用于将多核苷酸封装成减小尺寸的脂质纳米颗粒以及其新型调配物的方法 |
| BR112023001648A2 (pt) | 2020-07-27 | 2023-04-04 | Anjarium Biosciences Ag | Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo |
| AU2021336976A1 (en) | 2020-09-03 | 2023-03-23 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| GB202014751D0 (en) | 2020-09-18 | 2020-11-04 | Lightbio Ltd | Targeting vector |
| IL303195A (en) | 2020-11-25 | 2023-07-01 | Akagera Medicines Inc | Lipid nanoparticles for delivery of nucleic acids and related methods of use |
| KR20230135585A (ko) | 2020-12-23 | 2023-09-25 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 변형된 trem의 조성물 및 이의 용도 |
| WO2022155195A1 (fr) * | 2021-01-12 | 2022-07-21 | Peranteau William | Nanoparticules de lipide ionisables destinées à l'administration in utéro d'arnm |
| JP2024512669A (ja) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用 |
| EP4333906A4 (fr) * | 2021-05-07 | 2025-04-02 | Generation Bio Co. | Compositions de vecteurs d'adn non viraux lyophilisées et leurs utilisations |
| EP4377457A1 (fr) | 2021-07-26 | 2024-06-05 | Flagship Pioneering Innovations VI, LLC | Compositions de trem et leurs utilisations |
| EP4124348A1 (fr) * | 2021-07-30 | 2023-02-01 | 4basebio UK Ltd | Nanoparticules pour l'administration de cellules |
| CN116179605B (zh) * | 2021-08-12 | 2025-11-11 | 蓝图生物医药(广州)有限公司 | 一种重组腺相关病毒载体及其应用 |
| EP4464783A3 (fr) | 2021-09-17 | 2025-01-22 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de production de polyribonucléotides circulaires |
| TW202322826A (zh) | 2021-10-18 | 2023-06-16 | 美商旗艦先鋒創新有限責任公司 | 用於純化多核糖核苷酸之組成物及方法 |
| IL313004A (en) | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Coronavirus immunogen compositions and their uses |
| IL312799A (en) | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions of varicella-zoster virus and uses thereof |
| EP4436598A2 (fr) | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Compositions immunogènes et leurs utilisations |
| EP4448758A1 (fr) | 2021-12-17 | 2024-10-23 | Flagship Pioneering Innovations VI, LLC | Procédés d'enrichissement en arn circulaire dans des conditions de dénaturation |
| CA3241061A1 (fr) | 2021-12-22 | 2023-06-29 | Alexandra Sophie DE BOER | Compositions et procedes de purification de polyribonucleotides |
| MX2024007870A (es) | 2021-12-23 | 2024-08-15 | Flagship Pioneering Innovations Vi Llc | Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos. |
| EP4436558B1 (fr) * | 2022-02-02 | 2025-09-24 | MSLsolutions GmbH | Procédé de production de médicaments et de vaccins |
| KR20240161965A (ko) * | 2022-03-14 | 2024-11-13 | 제너레이션 바이오 컴퍼니 | 이종 프라임 부스트 백신 조성물 및 사용 방법 |
| KR20240166554A (ko) | 2022-03-25 | 2024-11-26 | 세일 바이오메디슨스, 인크. | 신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법 |
| US20250228928A1 (en) * | 2022-04-04 | 2025-07-17 | Spark Therapeutics, Inc. | Immune enhancement and infectious disease treatment |
| WO2023196634A2 (fr) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccins et procédés associés |
| EP4522743A1 (fr) | 2022-05-09 | 2025-03-19 | Flagship Pioneering Innovations VI, LLC | Compositions de trem et procédés d'utilisation pour traiter des troubles prolifératifs |
| JP2025516638A (ja) | 2022-05-13 | 2025-05-30 | フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー | 二本鎖ｄｎａ組成物及び関連する方法 |
| JP2025522311A (ja) | 2022-05-25 | 2025-07-15 | アカゲラ・メディスンズ，インコーポレイテッド | 核酸を送達するための脂質ナノ粒子およびその使用方法 |
| WO2023250112A1 (fr) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions de trem modifiées et leurs utilisations |
| WO2024015428A1 (fr) * | 2022-07-12 | 2024-01-18 | Trustees Of Boston University | Voies de signalisation cellulaire synthétiques et leurs utilisations |
| AU2023320333A1 (en) | 2022-08-01 | 2025-01-16 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
| KR102544632B1 (ko) * | 2022-08-05 | 2023-06-16 | 주식회사 무진메디 | 장쇄 세라마이드가 포함된 지질 나노입자 및 이를 포함하는 세포 사멸용 조성물 |
| EP4569112A1 (fr) | 2022-08-12 | 2025-06-18 | Remix Therapeutics Inc. | Procédés et compositions pour moduler l'épissage au niveau de sites d'épissage alternatifs |
| KR20250056256A (ko) | 2022-08-31 | 2025-04-25 | 세일 바이오메디슨스, 인크. | 신규 이온화성 지질 및 지질 나노입자, 그리고 이의 사용 방법 |
| WO2024077191A1 (fr) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer |
| EP4612296A1 (fr) | 2022-10-31 | 2025-09-10 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de purification de polyribonucléotides |
| AR131008A1 (es) | 2022-11-08 | 2025-02-05 | Flagship Pioneering Innovations Vi Llc | Composiciones y métodos para producir polirribonucleótidos circulares |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| WO2024151685A1 (fr) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Molécules d'acide nucléique recombinant et leur utilisation dans la cicatrisation des plaies |
| WO2024151687A1 (fr) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Commutateurs génétiques et leur utilisation dans le traitement du cancer |
| US20240238473A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
| EP4648794A2 (fr) | 2023-01-09 | 2025-11-19 | Flagship Pioneering Innovations VII, LLC | Vaccins et procédés associés |
| TW202438515A (zh) | 2023-02-06 | 2024-10-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫調節組合物及相關方法 |
| EP4665736A2 (fr) | 2023-02-13 | 2025-12-24 | Flagship Pioneering Innovations VII, LLC | Lipides ionisables contenant un lieur clivable et supports lipidiques pour compositions thérapeutiques |
| IL322201A (en) | 2023-02-17 | 2025-09-01 | Flagship Pioneering Innovations Vii Llc | DNA structures containing modified uracil |
| EP4665856A2 (fr) | 2023-02-17 | 2025-12-24 | Flagship Pioneering Innovations VII, LLC | Compositions d'adn comprenant de la cytosine modifiée |
| WO2024182707A1 (fr) | 2023-03-02 | 2024-09-06 | Krystal Biotech, Inc. | Interleukine-2 et interleukine-12 pour le traitement du cancer |
| AU2024235803A1 (en) | 2023-03-15 | 2025-09-25 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising polyribonucleotides and uses thereof |
| WO2024192422A1 (fr) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Compositions immunogènes et leurs utilisations |
| KR20240149552A (ko) * | 2023-04-06 | 2024-10-15 | 주식회사 무진메디 | 수분산성이 우수한 고함량 세라마이드 조성물 |
| AU2024255972A1 (en) | 2023-04-12 | 2025-10-23 | Flagship Pioneering Innovations Vi, Llc | Modified trems, compositions, and related methods thereof |
| WO2024216128A1 (fr) | 2023-04-12 | 2024-10-17 | Flagship Pioneering Innovations Vi, Llc | Trems destinés à être utilisés dans la correction de mutations faux-sens |
| WO2024220746A2 (fr) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Agents d'arni ciblant la synthase d'acides gras et procédés associés |
| WO2024258829A1 (fr) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Compositions de vaccin contre le sars-cov-2 et procédés associés |
| WO2025006684A1 (fr) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Polyribonucléotides circulaires codant pour des polypeptides antifusogènes |
| TW202516001A (zh) | 2023-07-25 | 2025-04-16 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | Ｃａｓ內切酶及相關方法 |
| WO2025042786A1 (fr) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprenant des polyribonucléotides circulaires et leurs utilisations |
| WO2025049632A1 (fr) * | 2023-08-29 | 2025-03-06 | Rejuvenation Technologies Inc. | Compositions et méthodes pour l'administration large d'arn dans un tissu |
| WO2025054236A2 (fr) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Compositions de vaccin contre le sars-cov-2 et procédés associés |
| WO2025052180A2 (fr) | 2023-09-07 | 2025-03-13 | Axelyf ehf. | Lipides et nanoparticules lipidiques |
| WO2025064475A2 (fr) | 2023-09-18 | 2025-03-27 | Flagship Pioneering Innovations Vii, Llc | Compositions lipidoïdes ionisables et leurs utilisations thérapeutiques |
| WO2025072331A1 (fr) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Nucléases cas et procédés ou méthodes associés |
| WO2025096807A2 (fr) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Nouvelles formes d'adn thérapeutique |
| TW202535835A (zh) | 2023-11-14 | 2025-09-16 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 可電離類脂質組成物及其治療用途 |
| US20250161347A1 (en) | 2023-11-22 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Methods and compositions for treating non-alcoholic fatty liver disease |
| US20250375499A1 (en) | 2024-01-26 | 2025-12-11 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025194019A1 (fr) | 2024-03-14 | 2025-09-18 | Flagship Pioneering Innovations Vii, Llc | Méthodes de traitement de la fibrose hépatique et de la stéatose hépatique non alcoolique |
| WO2025217275A2 (fr) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Compositions ciblées sur des cellules immunitaires et procédés associés |
| US20250353881A1 (en) | 2024-05-16 | 2025-11-20 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025245188A2 (fr) | 2024-05-21 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Méthodes de traitement de la stéatose hépatique et d'une stéatose hépatique non alcoolique |
| WO2025245111A1 (fr) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Protéines de ciblage d'immunorécepteurs et procédés associés |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478745A (en) * | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5869305A (en) * | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| DE10066104A1 (de) * | 2000-09-08 | 2003-01-09 | Medigene Ag | Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung |
| EP1838853A2 (fr) * | 2005-01-06 | 2007-10-03 | Benitec, Inc. | Agents arni pour l'entretien de cellules souches |
| EP2816118B1 (fr) * | 2005-05-31 | 2018-10-17 | The Regents of the University of Colorado, a body corporate | Procédés pour administrer des gènes |
| EP1979485A2 (fr) | 2006-01-31 | 2008-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Vecteurs parvoviraux auto-complémentaires et leurs procédés de fabrication et d'utilisation |
| AU2016203992A1 (en) * | 2009-05-11 | 2016-06-30 | Berg Llc | Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| EP2500434A1 (fr) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique |
| US9943574B2 (en) * | 2012-06-27 | 2018-04-17 | Arthrogen B.V. | Combination for treating an inflammatory disorder |
| CA2891911C (fr) * | 2012-12-07 | 2023-03-07 | Alnylam Pharmaceuticals, Inc. | Formulations de particules lipidiques d'acide nucleique ameliorees |
| MX365409B (es) * | 2013-03-14 | 2019-05-31 | Shire Human Genetic Therapies | Composiciones de ácido ribonucleico mensajero del regulador transmembrana de fibrosis quística y métodos y usos relacionados. |
| CN105408486B (zh) * | 2013-05-21 | 2020-07-14 | 佛罗里达大学研究基金会有限公司 | 衣壳修饰的raav3载体组合物以及在人肝癌基因治疗中的用途 |
| EP4019506A1 (fr) * | 2013-12-19 | 2022-06-29 | Novartis AG | Lipides et compositions lipidiques pour l'administration d'agents actifs |
| EP3242945B1 (fr) * | 2015-01-07 | 2021-09-01 | Universitat Autònoma de Barcelona | Construction génique à vecteur unique comprenant des gènes de l'insuline et de la glucokinase |
| CA3021949C (fr) * | 2015-04-24 | 2023-10-17 | University Of Massachusetts | Constructions d'aav modifiees et utilisations de celles-ci |
| ES2913626T5 (en) * | 2015-12-22 | 2025-05-12 | Modernatx Inc | Compounds and compositions for intracellular delivery of agents |
| MX2018010633A (es) * | 2016-03-03 | 2019-06-13 | Univ Massachusetts | Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral. |
-
2018
- 2018-09-07 MX MX2020002501A patent/MX2020002501A/es unknown
- 2018-09-07 JP JP2020512808A patent/JP2020537493A/ja active Pending
- 2018-09-07 MY MYPI2020000655A patent/MY209906A/en unknown
- 2018-09-07 AU AU2018330208A patent/AU2018330208B2/en active Active
- 2018-09-07 US US16/644,574 patent/US20210059953A1/en not_active Abandoned
- 2018-09-07 BR BR112020004219-6A patent/BR112020004219A2/pt unknown
- 2018-09-07 KR KR1020207009733A patent/KR102696307B1/ko active Active
- 2018-09-07 CA CA3075180A patent/CA3075180A1/fr active Pending
- 2018-09-07 WO PCT/US2018/050042 patent/WO2019051289A1/fr not_active Ceased
- 2018-09-07 SG SG11202000765PA patent/SG11202000765PA/en unknown
- 2018-09-07 MA MA050096A patent/MA50096A/fr unknown
- 2018-09-07 EP EP18853914.2A patent/EP3679148A4/fr active Pending
- 2018-09-07 CN CN201880057740.5A patent/CN111295448A/zh active Pending
-
2020
- 2020-02-20 IL IL272799A patent/IL272799B2/en unknown
- 2020-02-28 CO CONC2020/0002262A patent/CO2020002262A2/es unknown
- 2020-03-06 PH PH12020500466A patent/PH12020500466A1/en unknown
-
2022
- 2022-11-02 JP JP2022176366A patent/JP2023002828A/ja active Pending
-
2024
- 2024-10-28 JP JP2024189114A patent/JP2025016593A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MY209906A (en) | 2025-08-11 |
| KR102696307B1 (ko) | 2024-08-16 |
| NZ761412A (en) | 2024-07-05 |
| SG11202000765PA (en) | 2020-03-30 |
| AU2018330208A1 (en) | 2020-02-27 |
| JP2025016593A (ja) | 2025-02-04 |
| PH12020500466A1 (en) | 2021-01-25 |
| EP3679148A1 (fr) | 2020-07-15 |
| AU2018330208B2 (en) | 2025-04-17 |
| RU2020110805A (ru) | 2021-10-11 |
| US20210059953A1 (en) | 2021-03-04 |
| WO2019051289A1 (fr) | 2019-03-14 |
| JP2023002828A (ja) | 2023-01-10 |
| MX2020002501A (es) | 2020-09-17 |
| WO2019051289A9 (fr) | 2019-05-23 |
| IL272799B1 (en) | 2025-07-01 |
| CN111295448A (zh) | 2020-06-16 |
| RU2020110805A3 (fr) | 2022-01-19 |
| BR112020004219A2 (pt) | 2020-09-08 |
| IL272799B2 (en) | 2025-11-01 |
| CO2020002262A2 (es) | 2020-05-29 |
| CA3075180A1 (fr) | 2019-03-14 |
| KR20200051708A (ko) | 2020-05-13 |
| JP2020537493A (ja) | 2020-12-24 |
| EP3679148A4 (fr) | 2021-06-09 |
| IL272799A (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50096A (fr) | Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux | |
| IL282995A (en) | Formulations of lipid nanoparticles | |
| MA49421A (fr) | Formulations d'arn | |
| IL271389A (en) | Targeted non-viral dna insertions | |
| EP3443092A4 (fr) | Compositions de conjugués d'acides nucléiques ciblés | |
| EP3554558A4 (fr) | Conjugués ciblant hsp90 et formulations de ces derniers | |
| PT3426285T (pt) | Formulações e doses de uricase peguilada | |
| MA46466A (fr) | Formulations pharmaceutiques de protéines à viscosité réduite | |
| EP3504229A4 (fr) | Régulation de l'expression génique à l'aide de nucléases modifiées | |
| HUE061564T2 (hu) | Új lipidek és lipid nanorészecske készítmények nukleinsavak bevitelére | |
| HUE055002T2 (hu) | Nukleinsav-konstrukciók és génterápiás vektorok Wilson-kór kezelésében történõ alkalmazásra | |
| EP3723811A4 (fr) | Conjugués ciblant hsp90 et formulations de ces derniers | |
| MA50354A (fr) | Anticorps ciblant le cd137 et leurs méthodes d'utilisation | |
| LT3265084T (lt) | Brutono tirozino kinazės inhibitoriaus farmacinės kompozicijos | |
| EP3688033A4 (fr) | Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose | |
| EP3413909A4 (fr) | Administration sous-cutanée d'adénovirus à double ciblage | |
| IL259468A (en) | The reference to formyl peptide receptor 2/lipoxin receptor 4a (fpr2/alx) for the treatment of heart disease | |
| EP3442544A4 (fr) | Méthodes améliorées d'administration de gènes | |
| EP3402510A4 (fr) | Compositions et formulations comprenant le cabazitaxel et de l'albumine sérique humaine | |
| EP3394099A4 (fr) | Formulations d'anticorps anti-il-10 modifiés | |
| EP3687559A4 (fr) | Compositions ciblant des macrophages associés à une tumeur et leurs méthodes d'utilisation | |
| HUE062806T2 (hu) | Vektorok Friedreich-ataxia kezelésére | |
| EP3302477A4 (fr) | Formulations pharmaceutiques pour la libération prolongée d'ester de dinalbuphine de sébacoyle | |
| ITUB20153542A1 (it) | Composizione cosmetica ad attivita' idratante | |
| MA46436A (fr) | Compositions comprenant de la relaxine et leurs méthodes d'utilisation |